
Anette Duensing

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2475284/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 8.e11-8.e18.	1.6	8
2	Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities. Frontiers in Oncology, 2022, 12, .	2.8	2
3	Targeting the translational machinery in gastrointestinal stromal tumors (CIST): a new therapeutic vulnerability. Scientific Reports, 2022, 12, 8275.	3.3	3
4	<scp>PARP</scp> inhibition in prostate cancer. Genes Chromosomes and Cancer, 2021, 60, 344-351.	2.8	2
5	Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery. Biomedicines, 2021, 9, 627.	3.2	5
6	Rearranged ERG confers robustness to prostate cancer cells by subverting the function of p53. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 736.e1-736.e10.	1.6	2
7	Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells. Journal of Biological Chemistry, 2020, 295, 15636-15649.	3.4	18
8	Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells. Scientific Reports, 2020, 10, 5178.	3.3	8
9	High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naÃ⁻ve metastatic prostate cancer –Results from a prospective pilot study using a 37 gene panel. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e17-637.e27.	1.6	12
10	The BRCA2 mutation status shapes the immune phenotype of prostate cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1621-1633.	4.2	38
11	Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs). Clinical Sarcoma Research, 2019, 9, 3.	2.3	26
12	Cullin 5 is a novel candidate tumor suppressor in renal cell carcinoma involved in the maintenance of genome stability. Oncogenesis, 2019, 8, 4.	4.9	9
13	The Impact of Hormonal Contraceptives on Breast Cancer Pathology. Hormones and Cancer, 2018, 9, 240-253.	4.9	5
14	What's the FOX Got to Do with the KITten? Regulating the Lineage-Specific Transcriptional Landscape in GIST. Cancer Discovery, 2018, 8, 146-149.	9.4	5
15	Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 161.e19-161.e30.	1.6	26
16	Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer. Scientific Reports, 2018, 8, 16708.	3.3	27
17	Genomic features of renal cell carcinoma with venous tumor thrombus. Scientific Reports, 2018, 8, 7477.	3.3	19
18	Mutations in BRCA2 and taxane resistance in prostate cancer. Scientific Reports, 2017, 7, 4574.	3.3	32

ANETTE DUENSING

#	Article	IF	CITATIONS
19	Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate. Oncotarget, 2017, 8, 4471-4483.	1.8	16
20	Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity. Nature Communications, 2016, 7, ncomms11845.	12.8	44
21	Targeting ETV1 in Gastrointestinal Stromal Tumors: Tripping the Circuit Breaker in GIST?. Cancer Discovery, 2015, 5, 231-233.	9.4	7
22	The DREAM complex in antitumor activity of imatinib mesylate in gastrointestinal stromal tumors. Current Opinion in Oncology, 2014, 26, 415-421.	2.4	9
23	Unbiased Compound Screening Identifies Unexpected Drug Sensitivities and Novel Treatment Options for Gastrointestinal Stromal Tumors. Cancer Research, 2014, 74, 1200-1213.	0.9	40
24	The DREAM Complex Mediates GIST Cell Quiescence and Is a Novel Therapeutic Target to Enhance Imatinib-Induced Apoptosis. Cancer Research, 2013, 73, 5120-5129.	0.9	72
25	New developments in management of gastrointestinal stromal tumors: regorafenib, the new player in the team. Gastrointestinal Cancer: Targets and Therapy, 2013, , 1.	5.5	3
26	Closing in on accurate risk prediction and disease management for patients with operable GIST. Lancet Oncology, The, 2012, 13, 220-221.	10.7	3
27	Synergistic induction of apoptosis by the Bclâ€2 inhibitor ABTâ€737 and imatinib mesylate in gastrointestinal stromal tumor cells. Molecular Oncology, 2011, 5, 93-104.	4.6	27
28	Genomic instability and cancer: Lessons learned from human papillomaviruses. Cancer Letters, 2011, 305, 113-122.	7.2	93
29	Targeted therapies of gastrointestinal stromal tumors (GIST)—The next frontiers. Biochemical Pharmacology, 2010, 80, 575-583.	4.4	32
30	Proapoptotic Activity of Bortezomib in Gastrointestinal Stromal Tumor Cells. Cancer Research, 2010, 70, 150-159.	0.9	37
31	Tripeptidyl Peptidase II Is Required for c-MYC-Induced Centriole Overduplication and a Novel Therapeutic Target in c-MYC-Associated Neoplasms. Genes and Cancer, 2010, 1, 883-892.	1.9	11
32	Daughter Centriole Elongation Is Controlled by Proteolysis. Molecular Biology of the Cell, 2010, 21, 3942-3951.	2.1	28
33	Centrosomes, Polyploidy and Cancer. Advances in Experimental Medicine and Biology, 2010, 676, 93-103.	1.6	33
34	A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification - implications for chemoprevention. Molecular Cancer, 2010, 9, 153.	19.2	28
35	Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors. Oncotarget, 2010, 1, 6-8.	1.8	6
36	Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors. Oncotarget, 2010, 1, 6-8.	1.8	6

ANETTE DUENSING

#	Article	IF	CITATIONS
37	Cullin 1 Functions as a Centrosomal Suppressor of Centriole Multiplication by Regulating Polo-like Kinase 4 Protein Levels. Cancer Research, 2009, 69, 6668-6675.	0.9	57
38	Human Papillomavirus 16 E7 Oncoprotein Attenuates DNA Damage Checkpoint Control by Increasing the Proteolytic Turnover of Claspin. Cancer Research, 2009, 69, 7022-7029.	0.9	80
39	Centrosome overduplication, chromosomal instability, and human papillomavirus oncoproteins. Environmental and Molecular Mutagenesis, 2009, 50, 741-747.	2.2	46
40	Analysis of centrosome overduplication in correlation to cell division errors in high-risk human papillomavirus (HPV)-associated anal neoplasms. Virology, 2008, 372, 157-164.	2.4	52
41	Soluble histone H2AX is induced by DNA replication stress and sensitizes cells to undergo apoptosis. Molecular Cancer, 2008, 7, 61.	19.2	38
42	Imatinib Mesylate Induces Quiescence in Gastrointestinal Stromal Tumor Cells through the CDH1-SKP2-p27Kip1 Signaling Axis. Cancer Research, 2008, 68, 9015-9023.	0.9	53
43	ERCC1-XPF Endonuclease Facilitates DNA Double-Strand Break Repair. Molecular and Cellular Biology, 2008, 28, 5082-5092.	2.3	268
44	HPV-16 E7 Reveals a Link between DNA Replication Stress, Fanconi Anemia D2 Protein, and Alternative Lengthening of Telomere–Associated Promyelocytic Leukemia Bodies. Cancer Research, 2008, 68, 9954-9963.	0.9	55
45	Centrosome-Mediated Chromosomal Instability and Steroid Hormones as Co factors in Human Papillomavirus-Associated Cervical Carcinogenesis: Small Viruses Help to Answer Big Questions. Advances in Experimental Medicine and Biology, 2008, 617, 109-117.	1.6	2
46	The Human Papillomavirus Type 16 E7 Oncoprotein Activates the Fanconi Anemia (FA) Pathway and Causes Accelerated Chromosomal Instability in FA Cells. Journal of Virology, 2007, 81, 13265-13270.	3.4	89
47	Histone H2AX Is a Mediator of Gastrointestinal Stromal Tumor Cell Apoptosis following Treatment with Imatinib Mesylate. Cancer Research, 2007, 67, 2685-2692.	0.9	86
48	Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Laboratory Investigation, 2006, 86, 981-986.	3.7	80
49	A role of the mitotic spindle checkpoint in the cellular response to DNA replication stress. Journal of Cellular Biochemistry, 2006, 99, 759-769.	2.6	9
50	p21Waf1/Cip1 Deficiency Stimulates Centriole Overduplication. Cell Cycle, 2006, 5, 2899-2902.	2.6	28
51	Viral carcinogenesis and genomic instability. , 2006, , 179-199.		12
52	Familial Gastrointestinal Stromal Tumor Syndrome: Phenotypic and Molecular Features in a Kindred. Journal of Clinical Oncology, 2005, 23, 2735-2743.	1.6	146
53	Guilt by association? p53 and the development of aneuploidy in cancer. Biochemical and Biophysical Research Communications, 2005, 331, 694-700.	2.1	73
54	Biology of Gastrointestinal Stromal Tumors:KITMutations and Beyond. Cancer Investigation, 2004, 22, 106-116.	1.3	70

ANETTE DUENSING

#	Article	IF	CITATIONS
55	Protein Kinase C Î, (PKCÎ) Expression and Constitutive Activation in Gastrointestinal Stromal Tumors (GISTs). Cancer Research, 2004, 64, 5127-5131.	0.9	117
56	Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene, 2004, 23, 3999-4006.	5.9	306
57	Cyclin-dependent kinase inhibitor indirubin-3′-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene, 2004, 23, 8206-8215.	5.9	69
58	KIT-Negative Gastrointestinal Stromal Tumors. American Journal of Surgical Pathology, 2004, 28, 889-894.	3.7	454
59	<i>PDGFRA</i> Activating Mutations in Gastrointestinal Stromal Tumors. Science, 2003, 299, 708-710.	12.6	2,158
60	Evaluating the volume ratio of bone marrow affected by fibrosis: A parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia. Human Pathology, 2003, 34, 391-401.	2.0	22
61	Centrosome Abnormalities and Genomic Instability by Episomal Expression of Human Papillomavirus Type 16 in Raft Cultures of Human Keratinocytes. Journal of Virology, 2001, 75, 7712-7716.	3.4	112
62	Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).		1